Baudax Bio, Inc. (BXRX)

About Baudax Bio

We currently have multiple therapeutic candidates across early, mid and late-stage clinical development, including a FDA approved non-opioid therapy for use in the acute care setting.

About Us

Our Innovative Pipeline

Our product pipeline contains valuable therapeutic product candidate options for patients and healthcare providers in acute care settings.

ANJESO (meloxicam) injection Product Pipeline

Latest News

Aug 6, 2020 • 4:05 PM EDT

Baudax Bio to Report Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 10, 2020

View Press Release

Aug 6, 2020 • 4:05 PM EDT

Baudax Bio to Report Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 10, 2020

View Press Release

Aug 6, 2020 • 7:00 AM EDT

Baudax Bio Secures Permanent J-Code (J1738) for ANJESO® from Centers for Medicare and Medicaid Services

View Press Release

Jul 30, 2020 • 4:05 PM EDT

Baudax Bio Announces Presentation of New Phase IIIb ANJESO® Data at the American Society of Colon and Rectal Surgeons 2020 Annual Scientific Meeting

View Press Release

Jul 20, 2020 • 7:00 AM EDT

Baudax Bio Secures Pharmacy Supplier Agreement with Vizient Inc. for ANJESO®

View Press Release

Jul 3, 2020 • 3:25 PM EDT

Baudax Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

View Press Release

Jun 15, 2020 • 7:00 AM EDT

Baudax Bio Announces Full Commercial Launch of ANJESO™ and Receipt of Unique C-Code and Pass-Through Payment Status Effective July 1, 2020

View Press Release

Jun 1, 2020 • 7:00 AM EDT

Baudax Bio Secures $50 Million Credit Facility

View Press Release

May 8, 2020 • 7:00 AM EDT

Baudax Bio Reports First Quarter 2020 Financial Results

View Press Release

May 5, 2020 • 7:00 AM EDT

Baudax Bio Announces Presentation of New Phase IIIb ANJESO™ Data at Digestive Disease Week 2020

View Press Release

Acute Care Therapeutics for Surgical Settings

About Baudax Bio

Our Innovative Pipeline

Latest News

Email Alerts